Journal article
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
Abstract
BACKGROUND: Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental growth factor, in the treatment of malignant ascites.
METHODS: In this double-blind, placebo-controlled, parallel-group, phase 2 study, patients with advanced chemoresistant ovarian cancer and …
Authors
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby J-F; Vergote I
Journal
The Lancet Oncology, Vol. 13, No. 2, pp. 154–162
Publisher
Elsevier
Publication Date
February 2012
DOI
10.1016/s1470-2045(11)70338-2
ISSN
1470-2045